Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, and its receptor Fas are critical for the shutdown of chronic immune responses [1] [2] [3] and prevention of autoimmunity 4, 5 . Accordingly, mutations in their genes cause severe lymphadenopathy and autoimmune disease in mice 6, 7 and humans 8, 9 . FasL function is regulated by deposition in the plasma membrane and metalloprotease-mediated shedding 10, 11 . Here we generated genetargeted mice that selectively lack either secreted FasL (sFasL) or membrane-bound FasL (mFasL) to resolve which of these forms is required for cell killing and to explore their hypothesized nonapoptotic activities. Mice lacking sFasL (FasL Ds/Ds ) appeared normal and their T cells readily killed target cells, whereas T cells lacking mFasL (FasL Dm/Dm ) could not kill cells through Fas activation. FasL Dm/Dm mice developed lymphadenopathy and hypergammaglobulinaemia, similar to FasL gld/gld mice, which express a mutant form of FasL that cannot bind Fas, but surprisingly, FasL Dm/Dm mice (on a C57BL/6 background) succumbed to systemic lupus erythematosus (SLE)-like autoimmune kidney destruction and histiocytic sarcoma, diseases that occur only rarely and much later in FasL gld/gld mice. These results demonstrate that mFasL is essential for cytotoxic activity and constitutes the guardian against lymphadenopathy, autoimmunity and cancer, whereas excess sFasL appears to promote autoimmunity and tumorigenesis through nonapoptotic activities.
Although Fas-induced apoptosis is thought to require extensive aggregation of pre-assembled Fas trimers [12] [13] [14] [15] , it has not been resolved whether mFasL, sFasL or both cause cell killing when expressed physiologically 4, 5 . It is also debated whether either or both of these forms of FasL may have non-apoptotic activities, such as induction of inflammatory responses 5, 16, 17 . Indeed, sFasL is capable of activating the NF-kB pathway ( Supplementary Fig. 1 and refs 18 and 19) . We sought to determine the physiological functions of mFasL and sFasL by generating gene-targeted mice that cannot shed FasL but do express mFasL (FasL Ds/Ds ) and mice that lack mFasL but are capable of producing sFasL (FasL Dm/Dm ). Studies using FasL overexpression in transfected cell lines showed that the former can be accomplished by mutating the sequences in the fasl gene encoding the amino acids required for metalloprotease-mediated cleavage [12] [13] [14] (Fig. 1a , Supplementary Fig. 2a, b, d) . Conversely, the latter can be achieved by replacing the sequences in the fasl gene encoding the transmembrane and intra-cellular regions of FasL with those encoding the signal peptide of the cytokine G-CSF [12] [13] [14] (Fig. 1a , Supplementary Fig. 2a, c, e ).
To verify that the mutations had the intended consequences, we compared the expression and subcellular localization of FasL in mitogenically activated T lymphocytes from FasL Ds/Ds , FasL Dm/Dm and wild-type (WT) mice. Immunofluorescent staining and confocal microscopic analysis of fixed cells showed that intracellular localization and levels of the FasL Ds and FasL Dm mutant proteins were comparable to those of WT FasL (Fig. 1b ). Enzyme-linked immunosorbent assay (ELISA) demonstrated that mitogen-activated T cells from FasL Dm/Dm and WT mice contained substantial levels of FasL in their supernatants, whereas FasL Ds/Ds T cells had significantly less ( Fig. 1c ). FasL in cellular supernatants can be found as either sFasL, derived by metalloprotease-mediated cleavage, or mFasL present on vesicles that had been shed by cells 12 . mFasL on vesicles can efficiently trigger Fas-mediated apoptosis in cultured cells 12 , although the physiological relevance of this remains unclear. Fast protein liquid chromatography (FPLC) and ultra-centrifugation revealed that, in contrast to FasL from supernatants of WT or FasL Dm/Dm T cells, a substantial fraction of FasL in supernatants of FasL Ds/Ds T cells resided in membranous fractions ( Supplementary Fig. 3 ). Finally, immunofluorescent cell surface staining and fluorescence-activated cell sorting (FACS) analysis identified significantly higher levels of mFasL on activated T cells from FasL Ds/Ds mice than in WT T cells ( Fig. 1d) , consistent with the notion that metalloprotease-mediated cleavage reduces the levels of mFasL [11] [12] [13] [14] . As we expected, no FasL was detected on the surface of FasL Dm/Dm T cells ( Fig. 1e ). These results verify that FasL Ds/Ds mice produce mFasL that cannot be shed by metalloproteases, whereas FasL Dm/Dm mice lack mFasL but produce sFasL.
FasL contributes to the killing of virus-infected and other target cells 4 , so we wanted to determine which form is essential to this action. We used mitogen-activated T cells from WT or the mutant fasl knockin mice as killers and the FasL-sensitive CH1 mouse B lymphoma cells ( Supplementary Fig. 4a , b) as targets. FasL Ds/Ds T cells killed CH1 cells with significantly higher efficiency than did WT T cells ( Fig. 2a ). In contrast, FasL Dm/Dm T cells possessed very poor cytotoxic activity, comparable to the T cells of FasL-deficient FasL gld/gld mice (Fig. 2b) . FasL neutralization inhibited the cytotoxicity of WT and FasL Ds/Ds T cells but did not further reduce the poor killing by FasL Dm/Dm or FasL gld/gld T cells ( Supplementary Fig. 4c -e), demonstrating that only mFasL triggered a FasL/Fas-dependent apoptotic process.
Restimulation of activated T cells in vitro causes activationinduced cell death (AICD), which is largely dependent on FasLmediated (paracrine and autocrine) Fas activation 4 . Stimulation with mitogenic antibodies to CD3 triggered AICD in FasL Ds/Ds T-cell blasts as efficiently as in WT T-cell blasts (Fig. 2c ). In contrast, AICD was abnormally reduced in FasL Dm/Dm T cells, to a similar extent as in their FasL gld/gld counterparts (Fig. 2d ). FasL neutralization significantly reduced AICD in WT and FasL Ds/Ds T cells but did not further diminish the already reduced killing ability of FasL Dm/Dm or FasL gld/gld T cells ( Supplementary Fig. 5 ). This is consistent with the notion that AICD involves FasL/Fas-dependent as well as FasL/ Fas-independent mechanisms 4, 20 . Collectively, these results demonstrate that mFasL but not sFasL is essential for Fas-induced killing of target cells and AICD, and they indicate that metalloproteasemediated cleavage of mFasL reduces the cytotoxic activity of activated T cells. This is consistent with certain findings using transfected cell lines overexpressing FasL [12] [13] [14] and with the notion that apoptosis induction requires not only binding of FasL trimers to pre-assembled Fas trimers but more extensive aggregation of Fas trimers [12] [13] [14] [15] . This contrasts with TNFa, which can kill TNF-R1 1 target cells in both its membrane-bound and its secreted form 4, 5 .
Defects in the AICD of mature T cells are thought to be the cause of the lymphadenopathy, hyper-gammaglobulinaemia and autoimmunity in mice and humans deficient in FasL (for example, FasL gld/gld ) or Fas (for example, Fas lpr/lpr ) 4 . As reported 21 , by ,14 weeks of age FasL gld/gld mice (on an inbred C57BL/6 background) started to show signs of lymphadenopathy and splenomegaly ( Fig. 3a, b ), including accumulation of large numbers of 'unusual' TCRa/b 1 CD4 2 CD8 2 B220 1 T cells ( Fig. 3c, d ). This was accompanied by hyper-gammaglobulinaemia ( Fig. 3e ) with high titres of anti-nuclear auto-antibodies ( Fig. 3f, g) . FasL Dm/Dm mice developed lymphadenopathy, splenomegaly, hypergammaglobulinaemia and anti-nuclear auto-antibodies at a similar rate and to a similar extent as FasL gld/gld mice ( Fig. 3 ). Remarkably, however, the titres of anti-DNA auto-antibodies were significantly higher in FasL Dm/Dm mice than in FasL gld/gld mice (67% versus 14% were symptomatic of SLE-like disease (.12 international units per millilitre, IU ml 21 ), P , 0.05; Fig. 3h ). In contrast, FasL Ds/Ds mice exhibited none of these abnormalities and had a normal lifespan (Supplementary Fig. 6 ). These results show that mFasL but not sFasL is essential for the killing of unwanted lymphocytes that is required to prevent lymphadenopathy, hyper-gammaglobulinaemia and accumulation of auto-antibodies. 
Figure 1 | Generation of mutant mice that specifically lack either sFasL or mFasL. a, Schematic diagram of the WT mouse fasl gene, the mutation for creating the FasL Ds allele and the mutation for creating the FasL Dm allele. To make FasL Ds , the metalloproteinase recognition site (middle sequence) was altered to prevent FasL shedding. To make FasL Dm , sequences encoding the human G-CSF signal sequence were fused in frame with those for the extracellular region of mouse FasL (lowest sequence) to preclude insertion of FasL into the plasma membrane but allowing secretion of FasL (sFasL). P, CYTO, TM and EXT represent the promoter, cytoplasmic, transmembrane and extracellular regions, respectively. The positions of polymerase chain reaction (PCR) primers used for genotyping of the gene-targeted mice are indicated. b, Immunofluorescent staining and confocal microscopy to demonstrate intracellular localization of FasL (green) in activated T cells from WT, FasL Ds/Ds and FasL Dm/Dm mice. DAPI (blue) was used to label nuclei. Scale bars represent 6 mm. c, ELISA to quantify the levels of FasL in the supernatants of activated T cells from WT, FasL Ds/Ds and FasL Dm/Dm mice. Each dot represents a single mouse and the bar indicates the mean 6s.d. FasL Ds/Ds T cells had significantly (P , 0.03) less FasL in their supernatants than WT T cells. d, e, Cell surface immunofluorescent staining and FACS analysis to measure expression of mFasL on activated T cells from WT, FasL Ds/Ds (d) and FasL Dm/Dm (e) mice. Gene-targeted mice that selectively lack sFasL are denoted DsFasL; those that lack mFasL are denoted DmFasL. Solid lines show staining with an anti-FasL antibody and dotted lines show staining with an isotype-matched control antibody. Values represent mean 6s.d. of mFasL 1 T cells from three independent experiments (P , 0.05 WT versus FasL Dm/Dm mice at 6 and 24 h; P , 0.05 WT versus FasL Ds/Ds mice at 6 h). For all experiments (b-e), T cells were stimulated with concanavalin A for 3 days, rested for 2 days in interleukin IL-2 (0 h) and then restimulated with phorbol 12-myristate 13-acetate (PMA) plus ionomycin for 6 or 24 h. FasL gld/gld mice express a mutated FasL gld protein (in membranebound and secreted form) that is unable to bind to its receptor Fas 7 , whereas the sFasL in the FasL Dm/Dm mice (like WT sFasL) can bind to Fas ( Supplementary Fig. 1 and refs [12] [13] [14] . If sFasL plays a role in inflammation, for example through NF-kB activation (Supplementary Fig. 1 and refs 18, 19) , we would expect significant differences in morbidity and mortality between FasL Dm/Dm and FasL gld/gld mice. It was therefore remarkable that FasL Dm/Dm mice became sick significantly earlier than FasL gld/gld mice ( Fig. 4a , median latency 58 versus 94 weeks; P , 0.0001). At autopsy 62% of terminally ill FasL Dm/Dm mice showed signs of SLE-like autoimmune disease, including cellular crescents, protein casts (Fig. 4b, c ), deposition of immunoglobulin IgM as well as IgG and complement in renal glomeruli ( Supplementary Fig. 7 ). In contrast, such pathologies were only rarely observed in FasL gld/gld mice, and then only at a considerably older age and with less severity. By 57 weeks about half of the FasL Dm/Dm mice but only ,15% of the FasL gld/gld mice had developed fatal SLE-like autoimmune kidney disease (Fig. 4b ).
By 20 weeks 46% of FasL Dm/Dm mice presented with very high (.3,000 ng ml 21 ) serum IgE levels and ,30% had developed severe dermatitis with lesions appearing on their ears and necks (Supplementary Fig. 8a, b ). Although not previously reported, we observed this autoimmune pathology also in some FasL gld/gld mice, albeit at decidedly lower incidence (,10%) and later in life than in the FasL Dm/Dm mice. In Fas lpr/lpr mice lymphadenopathy and accumulation of TCRa/b 1 CD4 2 CD8 2 B220 1 T cells are accompanied by abnormally increased serum levels of pro-inflammatory cytokines, including TNFa, IL-6, IFNc and FasL itself 22 . FasL was shown to activate NF-kB transcription factors and expression of pro-inflammatory cytokines and chemokines ( Supplementary Fig. 1 and refs 5, 18, 19) . We therefore hypothesized that FasL Dm/Dm mice may develop autoimmune disease more rapidly and at higher incidence than FasL gld/gld animals because only FasL Dm/Dm mice produce excess sFasL that can bind to its receptor Fas, which may then activate NF-kB and thereby drive production of pro-inflammatory cytokines ( Supplementary  Figs 8 and 9 ). Consistent with this idea, at 12 to 20 weeks FasL Dm/Dm mice contained substantial numbers of cells with high levels of nuclear (that is, active) p65/NF-kB in the spleen, liver (Supplementary Fig. 10 ) and kidneys (not shown) and high serum levels of TNFa ( Supplementary Fig. 8 ; P , 0.0001 for TNFa). These abnormalities were significantly less prevalent in FasL gld/gld mice and were not detected in FasL Ds/Ds or WT animals ( Supplementary Figs 8, 9 and 10).
Fas is expressed on hepatocytes and its activation causes apoptosis 23, 24 . FasL can also be found in the liver, produced by infiltrating T lymphocytes or resident myeloid cells, and it has therefore been hypothesized that FasL/Fas-induced apoptosis prevents tumorigenesis in the liver 25 . Interestingly, a significant fraction (27% by 78 weeks) of both strains of LETTERS FasL Dm/Dm mice developed hepatic tumours with deposits in the spleen and lungs (Fig. 4d, e ). Microscopically and by immuno-phenotype (Mac-1 1 Mac-2 1 F4/80 1 B220 2 Thy-1 2 CD3 2 ) these tumours were characteristic of histiocytic sarcoma (Fig. 4e, f and Supplementary Fig. 11 ), being composed of oval cells with eosinophilic cytoplasm and elongated or folded nuclei 26 . These tumours were transplantable in C57BL/6 mice ( Supplementary Fig. 11 ), confirming their malignant status. Histiocytic sarcoma was rarely seen in FasL Ds/Ds or FasL gld/gld animals and in C57BL/ 6 (WT) mice such tumours are observed only at very low frequency late in life (,5% .78 weeks 26, 27 ; Fig. 4d and Supplementary Fig. 6 ).
Our findings that mFasL but not sFasL is critical for AICD of T cells in vitro and for prevention of lymphadenopathy, hyper-gammaglobulinaemia and accumulation of auto-antibodies within the whole animal are consistent with the notion that repeated T-cell antigen receptor (TCR) stimulation kills chronically activated T cells that are specific for auto-antigens or persistent pathogens through FasL/Fas signalling, thereby preventing lymphadenopathy [1] [2] [3] [4] . The observation that FasL Dm/Dm mice develop SLE-like glomerulonephritis and histiocytic sarcoma considerably earlier and with higher incidence than FasL gld/gld mice indicates that the high levels of sFasL produced in the FasL Dm/Dm mice may promote autoimmunity and tumorigenesis (because unlike sFasL from FasL gld/gld mice, sFasL from FasL Dm/Dm mice can engage its receptor Fas 12, 13 ). sFasL from FasL Dm/Dm mice may achieve this by triggering non-apoptotic signalling pathways, such as NF-kB-dependent inflammatory processes. Alternatively, differences between FasL gld/gld and FasL Dm/Dm mice may be due to the fact that retrograde signalling through FasL 28, 29 can only occur in FasL gld/gld mice but not in FasL Dm/Dm mice, although upon challenge with influenza virus in vivo or stimulation with suboptimal doses of anti-CD3 antibodies in vitro, CD8 1 T-cell responses were indistinguishable in WT, FasL gld/gld and FasL Dm/Dm mice ( Supplementary  Figs 12 and 13 ). It is theoretically also possible that FasL Dm/Dm mice die earlier than FasL gld/gld mice because the FasL Dm mutation causes complete loss of function whereas FasL gld represents a partial loss-offunction mutation. For two reasons this appears unlikely: (1) lymphadenopathy and hyper-gammaglobulinaemia occur in the two mutant strains (FasL Dm/Dm and FasL gld/gld ) with comparable kinetics and magnitude (Fig. 3) , indicating that the two mutations do not differ markedly in their potency, and (2) histiocytic sarcoma has not been reported in FasL knockout mice 30 .
We therefore hypothesize that tumorigenesis may be driven by a combination of loss of mFasL-mediated apoptosis of cells undergoing transformation and sFasL/Fas-induced non-apoptotic signals, perhaps NF-kB-mediated stimulation of cell proliferation, survival or inflammation within an elevated cytokine milieu.
METHODS SUMMARY
Generation of FasL mutant mice. The mouse fasl locus and known restriction sites were used to construct the targeting vector and diagnose homologous recombination in embryonic stem cells and gene-targeted (FasL Dm/Dm , FasL Ds/Ds ) mice. Targeting knock-in vectors were made with the loxP/pGKNeo/ loxP cassette cloned into the Pac1 site. Targeting constructs for the mutant FasL mice ( Supplementary Fig. 2 ) were linearized and electroporated into C57BL/6derived Bruce-4 embryonic stem cells. Analysis of FasL mutant mice. All experiments with mice were performed according to the guidelines of the Animal Ethics committees of our institutions. Mice were killed at 6, 12 or 20 weeks for analysis and further cohorts were monitored daily for morbidity and killed when showing signs of illness. Tissues were fixed for microscopic analysis in 80% Histochoice (Amresco)/ 20% ethanol or 10% buffered formalin and embedded in paraffin; conventional histopathology was performed on haematoxylin plus eosin (H&E)-stained sections. For detailed methods of immunohistochemical staining, immunofluorescent staining, confocal microscopy, cell preparation, flow cytometric analysis, ELISA, AICD, chromatography, viral infection and target cell killing, T-cell proliferation assays and western blotting, see the online-only Methods.
Statistical analysis was performed using Student's t-test, log rank (Mantel-Cox) test for survival curves or one-way analysis of variance using Turkey's comparison test to compare multiple groups where appropriate.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Generation of FasL mutant mice. Knowledge of the mouse fasl locus and restriction sites was used to construct the targeting vectors and to set up Southern blotting and PCR strategies to diagnose homologous recombination in embryonic stem cells and gene-targeted FasL Dm/Dm , FasL Ds/Ds mice. Gene targeting knock-in vectors were constructed with the loxP/pGKNeo/loxP cassette cloned into the Pac1 site. Targeting constructs ( Supplementary Fig. 1 ) were linearized and electroporated into C57BL/6-derived Bruce-4 embryonic stem cells according to standard procedures. The neo cassette was removed by crossing heterozygous gene-targeted mice with Cre deleter mice 31 . For each of the mutations two or three independent strains were established on an inbred C57BL/6 background: FasL Ds/Ds strains del494, del510 and del511 and FasL Dm/Dm strains del478 and del480. Independent strains with the same mutation were found to have identical phenotypes. Immunohistochemical and immunofluorescent staining, confocal microscopy. Immunohistochemical staining was performed as previously described 32 using antibodies to S100 (Neomarkers), CD3** (Abcam), B220 (RA3-6B2), Mac-2 (M3/84.6.34), F4/80*, lysozyme (Abcam), and NF-kB p65** (sc-109, Santa Cruz) using optimized antigen recovery methods (*proteinase-K treatment; **microwave retrieval). Secondary staining was performed with biotinylated goat anti-rabbit IgG antibodies (Vector) or rat IgG-isotype-specific antibodies (Pharmingen), followed by incubation with the biotin-avidindiaminobenzine-based detection system (Vector-Elite standard). In all cases positive (spleen, lymph node, melanoma) and negative controls (isotypematched control Abs or normal serum) were used to verify the reliability of the results. The results of the immunohistochemically stained sections were graded semiquantitatively as described 33 : 1 5 75-100% of the neoplastic cells positive; 1/2 5 50-75 of the neoplastic cells positive; 2/1 5 25-50% of the neoplastic cells positive; rare 5 10-25% of the neoplastic cells positive; 2 5 ,10% of the neoplastic cells positive.
To stain for immune complex deposits, kidneys were snap-frozen in isopentane, sectioned, acetone-fixed, blocked with PBS/2% FCS, followed by staining with FITC-coupled goat antibodies specific to mouse IgM, IgG or IgA (Southern Biotechnology), blocked with mouse serum and then stained with anti-C1q antibodies (Abcam) followed by incubation with biotinylated mouse anti-rat Igk light chain monoclonal antibody (MAR 18.5), followed by staining with Cy5conjugated avidin (Amersham Pharmacia Biotech) in PBS/2% FCS with DAPI (to stain nuclei).
Anti-nuclear auto-antibodies in sera of mice were detected by staining using 1/100 serum dilutions of slides coated with HEp-2 human epithelial cells according to the manufacturer's instructions (Immuno Concepts). Anti-nuclear auto-antibodies levels were semi-quantitated according to brightness of fluorescence intensity on a scale of 0 (no fluorescence) to 31 (maximum fluorescence intensity).
To detect cytoplasmic FasL in activated T lymphocytes, cells were fixed with icecold methanol as previously described 34 and stained for FasL using MFL-3 (BD Pharmingen) or FLIM58 (MBL) monoclonal antibodies or, as a negative control, with a hamster IgG1/k Ig isotype-matched control monoclonal antibodies (BD Biosciences). Secondary staining was performed with biotinylated goat anti-Armenian Hamster IgG antibodies (Jackson ImmunoResearch) and detection with FITC-conjugated streptavidin (Caltag). All immunofluorescent staining was visualized by confocal microscopy (Leica). Cell preparation and flow cytometric analysis. Single cell suspensions were prepared from histiocytic sarcoma (tumour)-burdened livers or spleens by digestion for 20 min at room temperature (22 uC) with collagenase-DNAase followed by treatment with ethylene-diaminetetraacetic acid (EDTA) as described previously 35 . Aliquots of cell suspensions (2 3 10 6 ) were injected intravenously into each of three (non-irradiated) 6-8-week-old C57BL/6 mice. Histiocytic sarcoma cells were cultured in the high glucose version of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 50 mM 2-mercaptoethanol, 13 mM folic acid, 100 mM L-asparagine plus L929 fibroblast supernatant (5-10%). Cultured histiocytic sarcoma cells were trypsinized, washed, resuspended in PBS and 1 3 10 6 live tumour cells injected intravenously into C57BL/6 mice.
Single cell suspensions of spleen, lymph nodes, peripheral blood and liver were stained with FITC-or R-PE-conjugated surface marker specific monoclonal antibodies (RB6-8C5: anti-Gr-1, MI/70: anti-Mac-1, M3/84.6.34: anti-Mac-2, Ter119: anti-erythroid cell surface marker, F4/80: anti-macrophage surface marker, T24.31.2: anti-Thy-1, GK1.5: anti-CD4, 53.6.72: anti-CD8, RA3-6B2: anti-CD45R-B220, PK136: anti-NK1.1 (BD Biosciences)) plus the vital dye PI (1 mg ml 21 ) and analysed in a FACScan (Becton Dickinson). Surface Fas expression was detected by pre-blocking with anti-FccR antibody (24G2) 1 5% normal goat serum and staining with biotinylated anti-Fas monoclonal antibody Jo2 or a biotinylated isotype-matched control hamster IgG antibody (BD Biosciences) followed by incubation with R-PE-conjugated streptavidin (Caltag). Surface FasL expression was detected by pre-blocking with anti-FccR antibody (24G2) 1 5% normal rat serum and staining with FLAG-tagged FasL (Alexis) or FLAGtagged FasL Dm plus biotinylated anti-FLAG antibody or a biotinylated Ig isotypematched control antibody, followed by detection with R-PE-conjugated streptavidin (Caltag). ELISA. Serum immunoglobulin concentrations were determined by ELISA as described previously 36 , using sheep anti-mouse Ig antibodies (Silenus Laboratories) as a capture reagent, and developed with mouse Ig isotype-specific goat antibodies that had been conjugated with horseradish peroxidase (Southern Biotechnology). Purified myeloma proteins were used as standards (Sigma). Cytokine concentrations in sera were measured by ELISA using the appropriately matched pairs of antibodies specific to IL-6, IFNc, TNFa (BD Pharmingen) or FasL (R&D Systems, FasL Duoset kit) following the manufacturers' instructions. AICD and target cell killing. Lymph node or spleen cells were mitogenically stimulated for 3 days in culture with concanavalin A (2 mg ml 21 , Pharmacia) plus IL-2 (100 IU ml 21 ), washed in medium and then cultured in IL-2 for a further 2 days. The resulting activated T lymphoblasts were then restimulated in the presence of IL-2 for 6 h with PMA (2 ng ml 21 ) plus ionomycin (2 mg ml 21 ) or with monoclonal antibodies to CD3 (145-2C11) and CD28 (37N51) (coated on culture plates at 10 mg ml 21 in PBS).
Activated T cells were washed and used as effector cells at effector:target ratios of 50:1 to 3.125:1. As target cells we used the FasL-sensitive mouse CH1 B lymphoma cells (2 3 10 4 cells in 200 ml in 96-well plates) that had been labelled 24 h earlier with CFSE (Molecular Probes) as described 37 . After 24 h of co-culture, CH1 cell survival was determined by staining with PI, followed by FACS analysis with CFSE 1 PI 2 cells being considered as live CH1 target cells. Killing with FLAG-tagged FasL (10 ng ml 21 , Alexis) crosslinked with anti-FLAG M2 monoclonal antibody (1 mg ml 21 , Sigma) was used as positive control for CH1 cell killing.
For AICD, activated T lymphoblasts were prepared as described above. These cells were washed in medium and re-plated at 10 5 cells ml 21 on tissue culture plates that had been coated with anti-CD3 monoclonal antibody (145-2C11; 10 mg ml 21 ) or cultured in IL-2 alone. T-cell viability was determined after 6, 12 or 24 h by staining with PI plus FITC-conjugated annexin V.
The effects of Fas-Fc fusion proteins (100 ng ml 21 ; gift from A. Ashkenazi and S. Masters, Genentech) or an Ig isotype-matched mouse monoclonal antibody (Bcl-2-100) on inhibition of CH1 target cell killing or AICD were assessed by adding these reagents to the cultures 30 min before the start of the assay. Size-exclusion chromatography. The supernatants of activated T lymphocytes were concentrated 25 times and 200 ml aliquots loaded onto a column (Superdex-200 HR10/30; Pharmacia). Proteins were eluted in PBS at 0.5 ml min 21 and fractions analysed by a FasL-specific ELISA (see above). The column was calibrated with standard proteins: thyroglobulin (669 kDa), ferritin (Fer, 440 kDa), bovine serum albumin (67 kDa), ovalbumin (45 kDa) and RNase A (RibA, 13.7 kDa). Viral infections and measurements of anti-viral CD8 1 T-cell responses. Mice (6-8 weeks old) were inoculated intra-nasally with 10 4.5 plaque-forming units of the HKx31 (H3N2, X31) 38 influenza virus. Virus stocks were grown in the allantoic cavity of 10-day-old embryonated hen's eggs and stored in aliquots at 280 uC. Anti-viral T-cell immune responses were enumerated by staining cells from spleens or lymph nodes with phycoerythrin (R-PE)-labelled MHC class I/peptide tetrameric complexes specific for the H-2D b -restricted nucleoprotein (D b NP 367-374 ) epitope of influenza virus 39, 40 plus antibodies to CD8. To measure antigen-specific cytokine expression, CD8 1 T cells were stimulated in culture in the presence of 1 mM D b NP 367-374 peptide and 1 mg ml 21 Brefeldin A (Epicentre Biotechnologies) for 5 h. Cells were then stained for CD8a, fixed and permeabilized using the Cytofix/Cytoperm reagent (BD Biosciences) and co-stained for intracellular IFNc or TNFa. Intracellular granzyme B (Caltag) content of cells was measured after stimulation of the cells with 50 ng ml 21 PMA and 500 ng ml 21 ionomycin for 5 h (with 1 mg ml 21 Brefeldin A present for the last 2 h) and subsequent surface marker staining. Analysis was performed on an LSR II (BD Biosciences) and data analysed using Weasel flow cytometry analysis software. Cultures of NP-specific CD8 1 T cells and 51 Cr release assay. Spleen cells from mice infected intra-nasally with HKx31 influenza virus 9 days earlier were cultured for 5 days with 2 3 10 7 c-irradiated (1,000 rad) NP 367-374 -coated C57BL/6 spleen cells plus 10 IU ml 21 recombinant IL-2. Cytotoxicity was assessed by conventional 51 Cr-release assay using as targets EL4 cells (H-2 b ) pulsed with 1 mM NP 367-374 (ref. 41) . T-cell proliferation assay. Allogeneic CD8 1 T-cell responders were seeded on plates coated with suboptimal amounts of anti-CD3 antibodies (145-2C11) that were also coated with either murine Fas-Fc IgG fusion proteins or an Ig isotypematched control mouse monoclonal antibody (Bcl-2-100) as previously described 28 .
[3H]TdR uptake, a measure of proliferation of the allogeneic CD8 1 T cells, was determined as described 28 . Production and purification of FLAG-tagged FasL Dm protein. Recombinant sFasL used in this study, FLAG-tagged FasL Dm , was prepared from culture supernatants of 293T cells that had been transiently transfected using lipofectamine with an expression vector encoding FLAG-tagged FasL Dm 72 h earlier. Filtered supernatant was applied to a 2 ml anti-FLAG M2 antibody conjugated agarose column (Sigma). After extensive washing with PBS, bound proteins were eluted with 100 mg ml 21 FLAG peptide in PBS (Auspep). The fractions containing the recombinant proteins were concentrated to 0.5 ml using a Millipore Ultrafree-MC centrifugal filter unit with a regenerated cellulose membrane (molecular weight cut-off of 10 kDa) and subjected to size-exclusion chromatography for further purification using a pre-packed Superdex 200 column (GE Healthcare; 300 mm 3 10 mm internal diameter) operated at 0.4 ml min 21 in PBS. The column was calibrated with Bio-Rad standard containing thyroglobulin dimer (670 kDa), bovine c-globulin (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17.5 kDa) and vitamin B12 (1.35 kDa). Fractions (0.4 ml) containing FLAG-tagged sFasL Dm , as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis (using anti-FLAG monoclonal antibody), were pooled and the protein concentration quantified. Cell culture and western blot analysis for NF-kB pathway activation. NIH-3T3 cells were seeded at 5 3 10 5 per flask in DMEM containing 10% FCS, allowed to adhere overnight, washed and then cultured for 24 h in DMEM containing only 0.25% FCS 18 . The T-cell hybridoma 3DO.54.3, which are resistant to FasL/ Fas-induced apoptosis, were cultured in the high glucose version of DMEM supplemented with 10% fetal bovine serum, 50 mM 2-mercaptoethanol, 13 mM folic acid, 100 mM L-asparagine. Cell were stimulated for 1 h or 5 h with TNFa (10 ng ml 21 ), FLAG-tagged FasL (100 ng ml 21 ) (Alexis) plus anti-FLAG M2 antibodies (1-2 mg ml 21 ; Sigma) or FLAG-tagged mFasL Dm (0.2 or 1 mg ml 21 ; without addition of anti-FLAG antibodies). Cell lysates were prepared in RIPA lysis buffer, proteins were size-fractionated on polyacrylamide gels (Novex) and transferred to nitrocellulose membranes (Amersham Pharmacia). Non-specific binding of antibodies to membranes was blocked by incubation in PBS, 5% skimmed milk, 1% casein, 0.05% Tween-20. Membranes were then probed with the following antibodies: rabbit anti-phospho-IkBa (Ser32), rabbit anti-total
